Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged goods manufacturing company, has reportedly discontinued the development of its pipeline epilepsy therapy ADX71149, according to the company’s latest Q2 2024 financials report and information from FiercePharma.com. ADX71149, a positive allosteric modulator (PAM) of metabotropic glutamate receptor-2 (mGlu2), was developed in a discovery collaboration between J&J’s Janssen unit and Switzerland-based Addex Therapeutics, a partnership that began in 2004 and could have yielded up to EUR 109 million in milestone payouts to Addex.
The decision to terminate development comes as no surprise following the April report that ADX71149 failed to meet the primary endpoint in a Phase II trial involving 110 epilepsy patients as an adjunct therapy. At that time, Janssen was reportedly evaluating the remaining data before making a decision. The exclusion of ADX71149 from J&J’s Q2 financial report confirms the termination of both the molecule’s development and the partnership with Addex, as confirmed by J&J in an email to FiercePharma.- Flcube.com
